DAXOR CORP 10-Q Summary: Quarter Ended March 31, 2001
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended March 31, 2001. DAXOR Corporation operates in the medical technology sector, specifically focusing on Blood Volume Analyzers (BVA-100) and laboratory services including semen and blood banking. The company is transitioning its revenue model from direct equipment sales to lease or loaner plans, which impacts immediate income recognition.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Total Revenues | $647,626 | $717,736 |
| Operating Revenues | $140,077 | $211,559 |
| Dividend Income | $473,919 | $473,494 |
| Net Income | $40,511 | $93,993 |
| Net Income Per Share | $0.01 | $0.02 |
| Net Cash from Operating Activities | $124,810 | $211,777 |
| Total Assets | $47,523,754 | N/A |
| Total Liabilities | $10,305,117 | N/A |
| Shareholders' Equity | $37,218,637 | N/A |
| Loans Payable (Debt) | $1,885,737 | N/A |
| Cash and Equivalents | $57,012 | N/A |
Portfolio Details: Marketable securities (Available-for-Sale) totaled $46,660,425 at fair value with a cost basis of $22,418,493, resulting in a net unrealized gain of $24,241,932.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 9.8% compared to Q1 2000. This was driven by a shift in sales strategy for the Blood Volume Analyzer from direct sales (which generated $211,559 in operating revenue in 2000) to lease/loaner models, which defer income recognition.
- Investment Performance: The company recorded a loss of $8,704 on the sale of securities in 2001, contrasting with a gain of $8,242 in 2000. Additionally, the net unrealized holding gain on the investment portfolio decreased from $25.5 million (Dec 2000) to $24.2 million (Mar 2001).
- Profitability: Net income before taxes dropped from $95,353 in 2000 to $59,780 in 2001. Net income after taxes fell from $93,993 to $40,511.
- Debt Levels: Loans payable increased to $1,885,737 from $1,775,363 at the end of 2000, consisting of a $1 million bank loan and $885,737 in margin debt secured by securities.
Outlook, Risks, and Management Commentary
- Strategic Shift: Management is focusing on establishing distribution networks and evaluating nationwide sales forces versus independent dealers. Income from non-Company personnel sales has not yet been realized.
- Capital Needs: The company is evaluating the acquisition of additional capital to accelerate national and international marketing programs.
- Operational Risks: The "instrument loaner reagent plan" requires the use of company reserves and involves higher reagent costs, though it offers potential for higher ultimate returns. The company has limited experience to date to determine if sales or loaner plans will predominate.
- Liquidity: Management states the company has adequate resources for current marketing levels and localized services. However, cash on hand is relatively low ($57,012) compared to the significant value of the securities portfolio.
- Legal: There are no current or pending legal proceedings.
Investor Verification Checklist
- Revenue Recognition Timing: Verify the impact of the shift from direct sales to lease/loaner models on future quarterly revenue recognition.
- Portfolio Liquidity: Assess the reliance on the $46.6 million securities portfolio for liquidity, noting that $1.88 million of this is pledged as collateral for loans.
- Operating Cash Flow: Monitor the trend of operating cash flow, which declined significantly ($124k vs $211k) alongside the drop in operating revenues.
- Capital Expenditure Plans: Confirm if the company will proceed with acquiring additional capital for the proposed nationwide marketing expansion.
- Reagent Cost Margins: Evaluate the profitability of the loaner reagent plan given the noted higher reagent costs.